Your browser doesn't support javascript.
loading
MiR-326/Sp1/KLF3: A novel regulatory axis in lung cancer progression.
Wang, Rong; Xu, Jiali; Xu, Jing; Zhu, Wei; Qiu, Tianzhu; Li, Jun; Zhang, Meiling; Wang, Qianqian; Xu, Tongpeng; Guo, Renhua; Lu, Kaihua; Yin, Yongmei; Gu, Yanhong; Zhu, Lingjun; Huang, Puwen; Liu, Ping; Liu, Lianke; De, Wei; Shu, Yongqian.
Afiliação
  • Wang R; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Xu J; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Xu J; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Zhu W; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Qiu T; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Li J; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Zhang M; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Wang Q; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Xu T; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Guo R; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Lu K; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Yin Y; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Gu Y; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Zhu L; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Huang P; Department of Oncology, Liyang people's Hospital of Jiangsu Province, Liyang, China.
  • Liu P; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Liu L; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • De W; Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, China.
  • Shu Y; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Cell Prolif ; 52(2): e12551, 2019 Mar.
Article em En | MEDLINE | ID: mdl-30485570
ABSTRACT

OBJECTIVES:

To investigate the function and regulatory mechanism of Krüppel-like factor 3 (KLF3) in lung cancer. MATERIALS AND

METHODS:

KLF3 expression was analysed by qRT-PCR and Western blot assays. The proliferation, migration, invasion, cycle and apoptosis were measured by CCK-8 and EdU, wound-healing and Transwell, and flow cytometry assays. The tumour growth was detected by nude mouse tumorigenesis assay. In addition, the interaction between KLF3 and Sp1 was accessed by luciferase reporter, EMSA and ChIP assay. JAK2, STAT3, PI3K and p-AKT levels were evaluated by Western blot and IHC assays.

RESULTS:

The results indicated that KLF3 expression was elevated in lung cancer tissues. Knockdown of KLF3 inhibited lung cancer cell proliferation, migration and invasion, and induced cell cycle arrest and apoptosis. In addition, the downregulation of KLF3 suppressed tumour growth in vivo. KLF3 was transcriptionally activated by Sp1. miR-326 could bind to 3'UTR of Sp1 but not KLF3 and decreased the accumulation of Sp1, which further indirectly reduced KLF3 expression and inactivated JAK2/STAT3 and PI3K/AKT signaling pathways in vitro and in vivo.

CONCLUSIONS:

Our data demonstrate that miR-326/Sp1/KLF3 regulatory axis is involved in the development of lung cancer, which hints the potential target for the further therapeutic strategy against lung cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_other_respiratory_diseases / 6_trachea_bronchus_lung_cancer Assunto principal: Regulação Neoplásica da Expressão Gênica / Fator de Transcrição Sp1 / MicroRNAs / Fatores de Transcrição Kruppel-Like / Neoplasias Pulmonares Limite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Prolif Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_other_respiratory_diseases / 6_trachea_bronchus_lung_cancer Assunto principal: Regulação Neoplásica da Expressão Gênica / Fator de Transcrição Sp1 / MicroRNAs / Fatores de Transcrição Kruppel-Like / Neoplasias Pulmonares Limite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Prolif Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China
...